US equities |
NVDA $236.73 ▲+1.19% SPCX $166.76 ▲+4.91% MU $1,066.94 ▼-0.74% TSLA $377.68 ▲+1.91% MSFT $526.96 ▲+1.82% INTC $117.23 ▼-1.76% SNDK $1,731.20 ▲+0.65% META $742.78 ▲+2.02%
FinancialContent

Monopar Therapeutics Inc. - Common Stock (NQ:MNPR)

77.06 -0.91 (-1.16%)
Delayed Quote Updated: 10:00 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Monopar Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Recap: Monopar Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
MNPR Stock Earnings: Monopar Therapeutics Misses EPS for Q2 2024 ↗
MNPR stock results show that Monopar Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying ↗
 
Via Benzinga
News headline image
Monopar and NorthStar Amend & Extend Collaboration
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely ↗
Penny stocks are risky. It’s why we attach a warning to the tail-end of penny stock articles and why the SEC has a warning about them too. 
Via InvestorPlace
Topics Regulatory Compliance
News headline image
Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying ↗
 
Via Benzinga
News headline image
Monopar Announces CFO Succession
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024 ↗
MNPR stock results show that Monopar Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q4 2023 ↗
MNPR stock results show that Monopar Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. 
Via Benzinga
News headline image
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >